These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17178767)

  • 1. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes.
    Endo T; Ban M; Hirata K; Yamamoto A; Hara Y; Momose Y
    Drug Metab Dispos; 2007 Mar; 35(3):476-83. PubMed ID: 17178767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
    Spracklin DK; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
    Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
    Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
    Draper AJ; Madan A; Parkinson A
    Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
    Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
    Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
    Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes.
    Patten CJ; Smith TJ; Friesen MJ; Tynes RE; Yang CS; Murphy SE
    Carcinogenesis; 1997 Aug; 18(8):1623-30. PubMed ID: 9276639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
    Bourrié M; Meunier V; Berger Y; Fabre G
    J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
    Taguchi K; Konishi T; Nishikawa H; Kitamura S
    Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
    Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
    Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes.
    Li Y; Li NY; Sellers EM
    Eur J Drug Metab Pharmacokinet; 1997; 22(4):295-304. PubMed ID: 9512924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine.
    Endo T; Nakajima M; Fukami T; Hara Y; Hasunuma T; Yokoi T; Momose Y
    Pharmacogenet Genomics; 2008 Sep; 18(9):761-72. PubMed ID: 18698229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.
    Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
    Br J Pharmacol; 2003 Apr; 138(8):1465-74. PubMed ID: 12721102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
    Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
    J Pharmacol Exp Ther; 1996 May; 277(2):1010-5. PubMed ID: 8627511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
    Taavitsainen P; Juvonen R; Pelkonen O
    Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver.
    Sai Y; Yang TJ; Krausz KW; Gonzalez FJ; Gelboin HV
    Pharmacogenetics; 1999 Apr; 9(2):229-37. PubMed ID: 10376770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
    Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram.
    Madan A; Parkinson A; Faiman MD
    Drug Metab Dispos; 1995 Oct; 23(10):1153-62. PubMed ID: 8654205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1.
    Duescher RJ; Elfarra AA
    Arch Biochem Biophys; 1994 Jun; 311(2):342-9. PubMed ID: 8203896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
    Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
    Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.